ReviewReviews in cardiovascular medicine2026
The Interplay of Programmed Cell Death Networks in Cardiovascular Diseases: Mechanisms and Therapeutic Opportunities.
Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed cell death (PCD) encompasses multiple regulated processes, including apoptosis, pyroptosis, ferroptosis, and necroptosis. These pathways form an interconnected network that contributes to the pathogenesis of cardiovascular diseases (CVDs), including atherosclerosis and myocardial ischemia-reperfusion injury. This review highlights cell-type-specific PCD signatures, showing that endothelial cells predominantly undergo pyroptosis and ferroptosis, whereas macrophages exhibit multiple PCD modalities and complex pathological crosstalk. Moreover, the review systematically summarizes key regulatory pathways (e.g., Piezo1 [Piezo-type mechanosensitive ion channel component 1]/NLRP3 [NOD-like receptor family pyrin domain containing 3], and Nrf2 [nuclear factor erythroid 2-related factor 2]/HO-1 [heme oxygenase 1]/GPX4 [glutathione peroxidase 4]), as well as multi-target natural compounds (e.g., melatonin and Guizhitongluo Tablet) that show translational promise and advantages in modulating PCD networks. The review also provides critical insights into major bottlenecks in clinical translation, including nonspecific tissue distribution and the lack of pathway-specific biomarkers. Novel solutions, such as cardiomyocyte-specific delivery systems (e.g., CD47-targeted lipid nanoparticles) and validated biomarkers (prostaglandin-endoperoxide synthase 2 [PTGS2] for ferroptosis), are also proposed. Overall, this review advances our understanding of PCD network regulation in CVDs and proposes innovative precision therapeutic strategies that align with the evolving needs of cardiovascular translational medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.